Section Arrow
SKYE.NASDAQ
- Skye Bioscience
Quotes are at least 15-min delayed:2026/01/07 09:59 EST
Regular Hours
Last
 1.1475
+0.1375 (+13.61%)
Day High 
1.15 
Prev. Close
1.01 
1-M High
1.27 
Volume 
219.30K 
Bid
1.1
Ask
1.15
Day Low
1.07 
Open
1.09 
1-M Low
0.6844 
Market Cap 
32.38M 
Currency 美元 
P/E 3.58 
%Yield -- 
10-SMA 0.84 
20-SMA 0.97 
50-SMA 1.22 
52-W High 5.75 
52-W Low 0.6844 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.30/-1.43
Enterprise Value
32.65M
Balance Sheet
Book Value Per Share
1.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1428+0.0378+36.00%-- 
GLUEMonte Rosa Therapeutics23.1551+7.1451+44.63%54.09PE
VTYXVentyx Biosciences13.815+3.765+37.46%-- 
SLSSELLAS Life Sciences Group3.96-0.14-3.41%-- 
SLRXSalarius Pharmaceuticals Inc0.7088+0.0588+9.05%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.